Higher vitamin D levels in HIV‐infected out‐patients on treatment with boosted protease inhibitor monotherapy

• Published in: HIV medicine 2013-10, Vol.14 (9), p.556-562
• Main Authors: Cervero, M, Agud, JL, Torres, R, García‐Lacalle, C, Alcázar, V, Jusdado, JJ, Moreno, S
• Format: Article
• Language: English
• Subjects: Adult; African Continental Ancestry Group; Albumin; antiretroviral therapy; Antiretroviral Therapy, Highly Active - adverse effects; combination antiretroviral therapy; Cross-Sectional Studies; deficiency; Female; Heliotherapy; highly active antiretroviral therapy; HIV; HIV Infections - blood; HIV Infections - complications; HIV Infections - drug therapy; HIV Infections - virology; HIV Protease Inhibitors - adverse effects; HIV Protease Inhibitors - therapeutic use; Human immunodeficiency virus 1; Humans; Male; Outpatients; regimen; Spain - epidemiology; Viral Load; vitamin D; Vitamin D - blood; Vitamin D - therapeutic use; Vitamin D Deficiency - drug therapy; Vitamin D Deficiency - epidemiology; Vitamin D Deficiency - etiology; Young Adult
• ISSN: 1464-2662; 1468-1293
• DOI: 10.1111/hiv.12049

Objectives We investigated the vitamin D status of patients receiving frequently used types of combination antiretroviral therapy (cART), including boosted protease inhibitor (PI) monotherapy. Methods For this cross‐sectional study, out of 450 HIV‐infected patients followed in the Hospital Severo Ochoa (Madrid, Spain), we selected 352 patients for whom vitamin D levels had been measured (January 2009 to December 2010). We collected the following data: demographics, cART duration, main cART regimen, viral load (VL), CD4 cell count, and concentrations of 25(OH)‐vitamin D [25(OH)‐D], parathyroid hormone (PTH), albumin and calcium. Vitamin D status cut‐off points were: (1) deficiency (vitDd): 25(OH)‐D